These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 11786932)
1. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Naidu R; Wahab NA; Yadav M; Kutty MK Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932 [TBL] [Abstract][Full Text] [Related]
2. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Naidu R; Wahab NA; Yadav MM; Kutty MK Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618 [TBL] [Abstract][Full Text] [Related]
3. Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction. Naidu R; Wahab NA; Yadav M; Kutty MK; Nair S Int J Mol Med; 2001 Aug; 8(2):193-8. PubMed ID: 11445874 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of p53 expression in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty KK Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057 [TBL] [Abstract][Full Text] [Related]
5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Latta EK; Tjan S; Parkes RK; O'Malley FP Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013 [TBL] [Abstract][Full Text] [Related]
6. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of c-myc proto-oncogene in primary human breast carcinomas. Pavelic ZP; Steele P; Preisler HD Anticancer Res; 1991; 11(4):1421-7. PubMed ID: 1660688 [TBL] [Abstract][Full Text] [Related]
9. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019 [TBL] [Abstract][Full Text] [Related]
10. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Pavelic ZP; Pavelic L; Lower EE; Gapany M; Gapany S; Barker EA; Preisler HD Cancer Res; 1992 May; 52(9):2597-602. PubMed ID: 1348967 [TBL] [Abstract][Full Text] [Related]
11. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365 [TBL] [Abstract][Full Text] [Related]
12. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
13. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
14. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K Anticancer Res; 1995; 15(3):959-64. PubMed ID: 7645986 [TBL] [Abstract][Full Text] [Related]
15. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Sullivan PS; Apple SK Breast J; 2009; 15(2):146-54. PubMed ID: 19292800 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA Breast J; 2009; 15(2):120-32. PubMed ID: 19292797 [TBL] [Abstract][Full Text] [Related]
17. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120 [TBL] [Abstract][Full Text] [Related]
18. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420 [TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. Vos CB; Ter Haar NT; Peterse JL; Cornelisse CJ; van de Vijver MJ J Pathol; 1999 Feb; 187(3):279-84. PubMed ID: 10398079 [TBL] [Abstract][Full Text] [Related]
20. Concordant loss of fragile gene expression early in breast cancer development. Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]